How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity

Simply Wall St.08-22

Rhythm Pharmaceuticals recently announced that the UK’s Medicines and Healthcare products Regulatory Agency expanded marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2661219899?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-08-22 17:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661219899","market":"sg","top_or_hot":-1,"title":"How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity","media":"Simply Wall St.","content":"<div>\n<p>Rhythm Pharmaceuticals recently announced that the UK’s Medicines and Healthcare products Regulatory Agency expanded marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-exp\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>How Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHow Investors May Respond To Rhythm Pharmaceuticals (RYTM) Expanded UK Approval For IMCIVREE In Hypothalamic Obesity\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-22 17:21 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-exp><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Rhythm Pharmaceuticals recently announced that the UK’s Medicines and Healthcare products Regulatory Agency expanded marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-exp\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RYTM","symbol_name":"Rhythm Pharmaceuticals Inc.","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-exp","article_id":"2661219899","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rytm/rhythm-pharmaceuticals/news/how-investors-may-respond-to-rhythm-pharmaceuticals-rytm-exp","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2661219899","pubTimestamp":1787390490,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Rhythm Pharmaceuticals recently announced that the UK’s Medicines and Healthcare products Regulatory Agency expanded marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity in adults and children 4 years and older, and granted orphan drug designation based on positive Phase 2 and Phase 3 TRANSCEND data.\nThis regulatory shift materially broadens IMCIVREE’s addressable patient population in the UK’s rare obesity segment and underscores its clinically...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"RYTM":"Rhythm Pharmaceuticals Inc.","MEDI":"HARBOR HEALTH CARE ETF","BK4211":"区域性银行","BK4588":"碎股","AIPO":"Defiance AI and Power Infrastructure ETF","BK4585":"ETF&股票定投概念","ARTY":"ISHARES FUTURE AI & TECH ETF","ISBC":"投资者银行","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK4139":"生物科技","AGIX":"通用人工智能 ETF-AGIX","VTHR":"Vanguard Russell 3000 ETF","QTOC":"Innovator Growth Accelerated Plus ETF - October"},"translate_title":"投资者如何应对 Rhythm Pharmaceuticals (RYTM) 扩大英国对 IMCIVREE 治疗下丘脑肥胖的批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CHAT":0.61,"AIPO":0.71,"VTHR":0.61,"ARTY":0.61,"RYTM":1.5,"MEDI":0.6,"AGIX":0.61,"ISBC":1.5,"QTOC":0.61},"content_text":"Rhythm Pharmaceuticals recently announced that the UK’s Medicines and Healthcare products Regulatory Agency expanded marketing authorization for IMCIVREE (setmelanotide) to treat acquired hypothalamic obesity in adults and children 4 years and older, and granted orphan drug designation based on positive Phase 2 and Phase 3 TRANSCEND data. This regulatory shift materially broadens IMCIVREE’s addressable patient population in the UK’s rare obesity segment and underscores its clinically validated impact on body mass index and symptom control. We’ll now examine how this expanded UK authorization for acquired hypothalamic obesity could reshape Rhythm’s investment narrative and future growth drivers. Rare earth metals are the new gold rush. Find out which 28 stocks are leading the charge.AdvertisementRhythm Pharmaceuticals Investment Narrative RecapTo own Rhythm Pharmaceuticals, you need to believe IMCIVREE can support a durable rare obesity franchise even as the company absorbs ongoing losses and funds a broad pipeline from equity and future cash flows. The expanded UK authorization for acquired hypothalamic obesity is a positive incremental catalyst, but near term the key swing factor remains how quickly new indications translate into reimbursed patients while high R&D and SG&A keep net earnings negative and raise the risk of further dilution. The August 11 MHRA decision to broaden IMCIVREE’s label for acquired hypothalamic obesity, backed by Phase 2 and Phase 3 TRANSCEND data, sits squarely at the heart of Rhythm’s current catalyst story, because it directly tests the company’s ability to scale international access and reimbursement for its lead asset. How efficiently Rhythm works with the NHS to secure coverage for this larger rare obesity population will influence both revenue ramp potential and the company’s dependence on future capital raises. Yet investors should also be aware that if international reimbursement uptake is slower than expected... Read the full narrative on Rhythm Pharmaceuticals (it's free!)Rhythm Pharmaceuticals’ narrative projects $971.3 million revenue and $263.4 million earnings by 2029.Uncover how Rhythm Pharmaceuticals' forecasts yield a $139.47 fair value, a 27% upside to its current price.Exploring Other PerspectivesRYTM 1-Year Stock Price Chart Three Simply Wall St Community fair value estimates for Rhythm range from US$134 to US$477.90, underscoring how differently retail investors view the same business. Set this wide spread against Rhythm’s continued operating losses and reliance on new capital, then consider how those funding needs could influence the company’s ability to sustain its current growth ambitions.Explore 3 other fair value estimates on Rhythm Pharmaceuticals - why the stock might be worth over 4x more than the current price!Decide For YourselfDisagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.A great starting point for your Rhythm Pharmaceuticals research is our analysis highlighting 3 key rewards that could impact your investment decision.Our free Rhythm Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Rhythm Pharmaceuticals' overall financial health at a glance.No Opportunity In Rhythm Pharmaceuticals?Our top stock finds are flying under the radar-for now. Get in early:The future of work is here. Discover the 37 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.AI is about to change healthcare. These 41 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2661219899","isCrawlerRequest":true}